BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32106831)

  • 1. GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.
    Ueki S; Fujishima F; Kumagai T; Ishida H; Okamoto H; Takaya K; Sato C; Taniyma Y; Kamei T; Sasano H
    BMC Cancer; 2020 Feb; 20(1):161. PubMed ID: 32106831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and clinicopathological significance of glucocorticoid receptor, SGK1, and NDRG1 in hormone-naïve prostate carcinoma.
    Hata S; Shimada H; Sato N; Koshiishi M; Ise K; Ogata T; Yamashita S; Ito A; Sasano H; Nakamura Y
    Med Mol Morphol; 2022 Dec; 55(4):283-291. PubMed ID: 35861941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple Cancer Stem Cell Markers Predict Neoadjuvant Chemotherapy Resistance of Esophageal Squamous Cell Carcinoma.
    Agawa K; Yamashita K; Nakagawa A; Yamada K; Watanabe A; Mukohyama J; Saito M; Fujita M; Takiguchi G; Urakawa N; Hasegawa H; Kanaji S; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
    Anticancer Res; 2021 Aug; 41(8):4117-4126. PubMed ID: 34281882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GR-SGK1-NDRG1 Pathway as a Predictor of Recurrence and Prognosis in Lung Adenocarcinoma After Radical Surgery.
    Sasaki T; Nakamura Y; Hata S; Shimada H
    Anticancer Res; 2023 Jul; 43(7):2965-2974. PubMed ID: 37351994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Loc NVV; Vuong NL; Trung LV; Trung TT
    J Gastrointest Cancer; 2023 Dec; 54(4):1240-1251. PubMed ID: 36723785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased expression of NDRG1 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.
    Ando T; Ishiguro H; Kimura M; Mitsui A; Kurehara H; Sugito N; Tomoda K; Mori R; Takashima N; Ogawa R; Fujii Y; Kuwabara Y
    Dis Esophagus; 2006; 19(6):454-8. PubMed ID: 17069588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma.
    Nakajima S; Mimura K; Saito K; Thar Min AK; Endo E; Yamada L; Kase K; Yamauchi N; Matsumoto T; Nakano H; Kanke Y; Okayama H; Saito M; Neupane P; Saze Z; Watanabe Y; Hanayama H; Hayase S; Kaneta A; Momma T; Ohki S; Ohira H; Kono K
    Mol Cancer Res; 2021 Jun; 19(6):1085-1095. PubMed ID: 33674443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of the kinase gene
    Godbole M; Togar T; Patel K; Dharavath B; Yadav N; Janjuha S; Gardi N; Tiwary K; Terwadkar P; Desai S; Prasad R; Dhamne H; Karve K; Salunkhe S; Kawle D; Chandrani P; Dutt S; Gupta S; Badwe RA; Dutt A
    J Biol Chem; 2018 Dec; 293(50):19263-19276. PubMed ID: 30337371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1).
    He S; Zhang H; Xiao Z; Bhushan S; Gao K; Wang W
    Bioengineered; 2021 Dec; 12(1):601-614. PubMed ID: 33517828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.
    Murakami T; Shoji Y; Nishi T; Chang SC; Jachimowicz RD; Hoshimoto S; Ono S; Shiloh Y; Takeuchi H; Kitagawa Y; Hoon DSB; Bustos MA
    Mol Oncol; 2021 Apr; 15(4):1069-1087. PubMed ID: 33605536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid receptor and serum- and glucocorticoid-induced kinase-1 in esophageal adenocarcinoma and adjacent Barrett's esophagus.
    Gokon Y; Fujishima F; Taniyama Y; Ishida H; Yamagata T; Sawai T; Uzuki M; Ichikawa H; Itakura Y; Takahashi K; Yajima N; Hagiwara M; Nishida A; Ozawa Y; Sakuma T; Sakamoto K; Zuguchi M; Saito M; Kamei T; Sasano H
    Pathol Int; 2020 Jun; 70(6):355-363. PubMed ID: 32173971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic but non-essential role of N-myc downstream regulated gene 1 in the progression of esophageal squamous cell carcinoma.
    Wei W; Bracher-Manecke JC; Zhao X; Davies NH; Zhou L; Ai R; Oliver L; Vallette F; Hendricks DT
    Cancer Biol Ther; 2013 Feb; 14(2):164-74. PubMed ID: 23192272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum- and glucocorticoid-inducible kinase 1 sensitive NF-κB signaling in dendritic cells.
    Schmid E; Xuan NT; Zahir N; Russo A; Yang W; Kuhl D; Faggio C; Shumilina E; Lang F
    Cell Physiol Biochem; 2014; 34(3):943-54. PubMed ID: 25200670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
    Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H
    Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Nagai Y; Yoshida N; Baba Y; Harada K; Imai K; Iwatsuki M; Karashima R; Koga Y; Nomoto D; Okadome K; Ishimoto T; Imamura Y; Watanabe M; Baba H
    Dig Endosc; 2020 Jan; 32(1):39-48. PubMed ID: 31120560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Prealbumin Level Measurement Before Neoadjuvant Chemotherapy in Elderly Patients With Locally Advanced Esophageal Cancer.
    Suematsu H; Yamada T; Onuma S; Hashimoto I; Kanematsu K; Nagasawa S; Aoyama T; Ogata T; Rino Y; Saito A; Oshima T
    In Vivo; 2024; 38(1):334-340. PubMed ID: 38148082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.